The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
The Center for Process Innovation (CPI), the process manufacturing arm of the UK government’s network of Catapult centers that are designed to encourage innovation in specific areas, is partnering with GlaxoSmithKline and AstraZeneca to establish a...
Novo Nordisk plans to invest DKK 650 million ($98 million) in upgrading and expanding facilities at its production site in Kalundborg, Denmark.
The facilities targeted for investment manufacture a range of products for diabetes treatments and will...
Merck KGaA has announced an investment of EUR 150 million ($169 million) in its manufacturing site at Aubonne, Switzerland to expand manufacturing capacity for its biologic-based medicines.
The investment will cover a new building dedicated to...
AveXis, a Novartis company, has signed an agreement to purchase an advanced biologics therapy manufacturing campus in Longmont, Colorado, to expand its manufacturing capacity for its investigational gene therapy, Zolgensma (onasemnogene...
Novartis reports that it has a legal dispute with Amgen regarding the companies’ collaboration agreements in the field of migraine. On April 2, 2019, Amgen issued a notice of termination of its migraine collaboration agreements with Novartis based...
Regeneron Pharmaceuticals, a Tarrytown, New York-based biopharmaceutical company, and Alnylam Pharmaceuticals, a Cambridge, Massachusetts-based company developing RNA interference (RNAi) therapeutics, have formed a collaboration, worth up to $1...
Novartis has completed the spin-off of Alcon, its eye-care device business, through a dividend-in-kind distribution to holders of Novartis shares and American depositary receipts (ADRs), with each holder receiving one Alcon share for every five...
Boehringer Ingelheim has completed the investment of EUR 105 million ($118 million) to expand associated production operations at its sites in Dortmund and Ingelheim, Germany for its Respimat inhaler.
Respimat is a propellant-free inhaler and the...
Xellia Pharmaceuticals, a specialty pharmaceutical company focused on anti-infective treatments and globally headquartered in Copehangen, Denmark, has entered into an agreement to divest its Raleigh, North Carolina manufacturing plant to Sagent...
Glenmark Pharmaceuticals, a Mumbai, India-headquartered pharmaceutical company, has appointed Alessandro Riva, MD, as Chief Executive Officer of its new innovation company. Dr. Riva is currently Executive Vice President, Oncology Therapeutics and...
US Food and Drug Administration Commissioner Scott Gottlieb has announced that he will be leaving his post in the next month. He made the announcement on March 5 (2019) and cited family commitments as the reason for his departure.
“This is a very...
The US Food and Drug Administration (FDA) is updating the agency’s ongoing investigation surrounding the recent voluntary recalls of multiple generic “sartan”-containing products, angiotensin II receptor blockers (ARBs), used to treat high blood...
Endo International, a generics and specialty branded pharmaceutical company, has announced that its subsidiaries, Endo Ventures Limited, Par Pharmaceutical, Inc. and Par Formulations Private Limited, have terminated their respective agreements to...
Novartis and Blackstone Life Sciences, a private investment firm, have launched Anthos Therapeutics, a new biopharmaceutical company focused on advancing targeted therapies for high-risk cardiovascular patients. The company will be based in...
Biogen has entered into an agreement to acquire Nightstar Therapeutics (NST), a clinical-stage gene- therapy company based in London, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders.
Under the terms of...
